Policy

Perceptions and Policies Still Holding Back Biosimilars in Europe

November 5th 2019

By Kelly Davio

During the International Society for Pharmacoeconomics and Outcomes Research 2019 meeting being held in Copenhagen, Denmark, 3 teams of researchers presented findings that show that, despite the fact that Europe’s biosimilars market is far more mature than that of the United States, the region still sees setbacks from stakeholder perceptions of biosimilars and from policies that do not adequately incentivize biosimilar use.

The Top 5 Biosimilars Articles for the Week of October 28

November 1st 2019

The Center for Biosimilars® recaps the top stories for the week of October 28, 2019.

Senate Bill From Collins, Smith Aims to Tackle Drug Shortages

October 31st 2019

By The Center for Biosimilars Staff

A bipartisan bill introduced in the Senate this week aims to address the growing issue of drug shortages.

In ASCO Survey, a Majority of US Patients With Cancer Report Anxiety Related to Cost

October 30th 2019

By Kelly Davio

The American Society of Clinical Oncology (ASCO) today released its third annual National Cancer Opinion Survey, results of which highlight the added stress that the financial burden of treatment places on patients with cancer.

Bipartisan Patent Transparency Bill Introduced in House of Representatives

October 28th 2019

By Allison Inserro

A bipartisan bill to require patent transparency in an effort to bring down the cost of prescription drugs has been introduced in the House of Representatives; the bill is a piece of companion legislation to one introduced in the Senate in March.

House GOP Lays Out Healthcare Vision in Blueprint

October 23rd 2019

By Allison Inserro

Republicans in the House of Representatives this week laid out their alternative to the Affordable Care Act (ACA) in an effort to position themselves against various Democratic healthcare proposals. The document contains many ideas that have been debated previously when Republicans tried to repeal the ACA, and it draws on work from the Heritage Foundation and the Cato Institute.

List Prices for Medicare Part D Drugs Exceeded Inflation in 2016, 2017, Analysis Says

October 21st 2019

By Allison Inserro

While some data suggest that overall drug price increases may have moderated recently, prices for specific drugs continue to rise at rates above inflation.

Pelosi Drug Pricing Bill Now Includes Amendment to Boost Biosimilars

October 18th 2019

By Allison Inserro

H.R. 3, The Lower Drug Costs Now Act, passed 2 committees in the House of Representatives Thursday, with a bipartisan amendment intended to boost uptake of biosimilars tucked inside.

Employer Groups Form Coalition on Drug Affordability, Support Policies Addressing Biosimilars

October 18th 2019

By Kelly Davio

A trio of employer groups has formed a new partnership to advocate for policies that address the problem of high—and growing—drug costs.

Bill to Create CMS Star Ratings Program for Biosimilars Introduced in House

October 16th 2019

By Kelly Davio

Representatives Paul Tonko, D-New York, and Rob Gibbs, R-Ohio, have introduced H.R. 4629, the Star Ratings for Biosimilars Act, in the House. The bipartisan bill would require HHS to evaluate Medicare Advantage (MA) plans based on whether biosimilars are available to enrollees.